(QURE) uniQure N.V. ANSOFF Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(QURE) uniQure N.V. Complete Analysis Pack
Go Beyond the Preview—Access the Full Ansoff Matrix Analysis
This uniQure N.V. Ansoff Matrix Analysis maps growth options across market penetration, market development, product development, and diversification to help with research, strategy, or investment decisions; this page includes a real preview/sample of the analysis so you can inspect style and substance before buying. Purchase the full version to receive the complete, ready-to-use company-specific Ansoff Matrix report.
Market Penetration
HOPE-B Phase III hemophilia B
uniQure is using etranacogene dezaparvovec to deepen its core hemophilia B position, and HOPE-B is the key Phase III proof point. In the pivotal trial, 54 adults with severe or moderately severe hemophilia B showed a median 54% factor IX activity at 24 months and a 77% bleed reduction, supporting stronger share gains in a rare-disease market. This is direct market penetration, not expansion into a new category.
AMT-060 hemophilia B Phase I/II
AMT-060 hemophilia B Phase I/II gives uniQure a second program in the same rare-disease franchise, so it can deepen share where it already has the clearest focus. Hemophilia B affects about 1 in 25,000 male births, and that limited pool makes repeat presence in the same niche more valuable. By adding clinical depth to one of its most established areas, uniQure reinforces brand, data, and prescriber trust.
Two hemophilia B gene therapies
uniQure N.V. is concentrating on one disease: hemophilia B. AMT-061, now HEMGENIX, won FDA approval in 2022 and carries a U.S. list price of $3.5 million, while AMT-060 built earlier clinical know-how. This two-asset setup deepens medical awareness and supports faster uptake in a niche with about 1 in 30,000 male births.
Rare severe genetic disease focus
uniQure N.V. keeps its market penetration tight by focusing on rare, severe genetic diseases where unmet need is highest. That niche fits its known treatment setting in hemophilia and other debilitating disorders, and it reinforces hard-won expertise in ultra-rare patients, specialist centers, and gene therapy delivery.
That is classic penetration: serve a defined buyer group more deeply instead of chasing broad demand. uniQure’s lead gene therapy, HEMGENIX, is already approved in the US for hemophilia B, giving the Company a real-world base to strengthen trust and repeat use in high-need rare disease markets.
- Focuses on ultra-rare, severe patients
- Uses specialist treatment centers
- Builds on hemophilia gene therapy know-how
- Supports deeper share in known markets
Amsterdam-based specialist platform
uniQure N.V., founded in 1998 and headquartered in Amsterdam, uses its long operating history to deepen its gene therapy base rather than chase broad-market expansion. That 25+ year track record supports repeat use of its clinical, regulatory, and manufacturing know-how in the same focused niche.
- 1998 founding supports credibility
- Amsterdam HQ anchors specialist focus
- Market penetration means depth, not breadth
- Clinical continuity strengthens trust
HEMGENIX Drives uniQure’s Hemophilia B Commercial Base
uniQure’s market penetration centers on hemophilia B, where HEMGENIX gives the Company a commercial base in an ultra-rare niche. In HOPE-B, 54 adults had a 54% median factor IX activity at 24 months and a 77% bleed reduction, supporting deeper use in the same patient pool. HEMGENIX has a U.S. list price of $3.5 million.
| Metric | Value |
|---|---|
| HOPE-B patients | 54 |
| Factor IX activity | 54% at 24 months |
| Bleed reduction | 77% |
| HEMGENIX U.S. list price | $3.5 million |
What is included in the product
Detailed Word Document
Provides a clear Ansoff Matrix framework for analyzing uniQure N.V.’s growth strategy
Editable Excel File
Provides a clear uniQure N.V. Ansoff Matrix snapshot to quickly align growth strategy across existing and new therapies and markets.
Reference Sources
Provides a concise, traceable list of primary sources validating uniQure N.V. growth-path assumptions for Ansoff Matrix analysis.
Market Development
AMT-130 Huntington’s disease
uniQure is using its AAV gene-therapy platform to move from rare-disease work into Huntington’s disease with AMT-130, now in Phase I/II testing. That shifts an existing capability into a new therapeutic market, since Huntington’s affects about 1 in 7,000 people in the U.S. and has no curative treatment. Early clinical data support the market-development case, with 2026 attention centered on dose, safety, and huntingtin lowering.
AMT-210 Parkinson’s disease
AMT-210 moves uniQure from hemophilia B into Parkinson’s disease, a much larger neurological market that affects about 10 million people worldwide. The program uses the same AAV gene-therapy platform, so it is a direct market-development play: one technology, a new patient base. If successful, it broadens uniQure’s addressable market beyond rare blood disorders and into a high-need CNS space.
AMT-260 temporal lobe epilepsy
AMT-260 is uniQure N.V.’s move into temporal lobe epilepsy, a new indication that expands its gene therapy platform into central nervous system disease. Epilepsy affects about 50 million people worldwide, and about 30% of patients remain drug-resistant, so the unmet need is large. This is market development: one tech, new disease market, bigger addressable pool.
AMT-161 ALS
AMT-161 marks uniQure N.V.’s move into amyotrophic lateral sclerosis, showing the company is taking its gene therapy platform into another severe neurodegenerative field. ALS is rare but deadly, with about 5,000 new U.S. cases each year and median survival of 2 to 5 years after diagnosis. That makes this a clear market development step, not just a product tweak.
- New clinical field: ALS
- Platform reused in a severe unmet-need market
- High-risk, high-value expansion
AMT-240 autosomal dominant Alzheimer’s disease
AMT-240 is an early preclinical move by uniQure N.V. into autosomal dominant Alzheimer’s disease, a rare, genetically defined market that sits far outside its hemophilia base. ADAD is under 1% of Alzheimer’s cases, so this is a small but high-value entry point for a first-in-class gene therapy. If it works, it broadens uniQure’s reach from rare bleeding disorders into neurodegeneration.
- Preclinical first step
- New Alzheimer’s market
- Rare, gene-driven target
- Diversifies beyond hemophilia
uniQure Expands Its AAV Platform Into Massive CNS Markets
uniQure N.V. is using one AAV platform to enter new CNS markets: Huntington’s, Parkinson’s, epilepsy, ALS, and preclinical ADAD. These are true market-development bets because the tech is reused while the patient base expands. The biggest pools are Parkinson’s at about 10 million people worldwide and epilepsy at about 50 million.
| Program | New market | Stage |
|---|---|---|
| AMT-130 | Huntington’s | Phase I/II |
| AMT-210 | Parkinson’s | R&D |
| AMT-260 | Epilepsy | R&D |
Get Your Copy
uniQure N.V. Reference Sources
This is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.
Product Development
Etranacogene dezaparvovec AMT-061
Etranacogene dezaparvovec AMT-061 is uniQure N.V.'s lead gene therapy and its most advanced program, anchored by the HOPE-B Phase III trial in hemophilia B. It fits Ansoff product development: a new therapy for an existing disease market, aiming at patients needing durable factor IX control. In HOPE-B, the company reported sustained factor IX activity and a 64% annualized bleed-rate reduction versus lead-in.
AMT-060 hemophilia B follow-on
AMT-060 adds product depth in uniQure N.V.’s core hemophilia B franchise, targeting the same market as its later-stage gene therapy. In Phase I/II, it serves as an earlier follow-on asset that can widen the company’s clinical and commercial options without leaving the FIX defect space. That matters in a market where even FIX activity above 5% can cut severe bleeding risk.
Phase III to Phase I/II pipeline ladder
uniQure N.V. runs a laddered pipeline from Phase I/II into Phase III, with multiple rare-disease gene therapy programs instead of a single-asset bet. That setup supports repeat product creation in the same niche market, which fits an Ansoff product-development move. Its late-stage asset HEMGENIX also gives commercial proof while newer candidates progress through the clinic.
Hemophilia B product family
uniQure N.V.’s hemophilia B franchise is a true product-development story: AMT-061, now etranacogene dezaparvovec (Hemgenix), is the lead asset, while AMT-060 is the earlier-stage predecessor in the same disease area. Hemgenix showed a 54% mean factor IX activity at 104 weeks in HOPE-B, supporting one franchise built on the same biology.
- AMT-061: lead hemophilia B gene therapy
- AMT-060: earlier-stage hemophilia B asset
- Same disease franchise, lower R&D risk
- HOPE-B: 54% mean FIX activity at 104 weeks
Clinical-stage innovation engine
uniQure keeps turning research into product candidates, with a clinical pipeline built around AMT-130, AMT-191, and AMT-260 across severe genetic diseases. That repeatable engine matters in Ansoff terms: it deepens product development inside markets that already need one-time gene therapies. As of 2025, uniQure had 3 clinical-stage assets, showing the platform is not a one-off.
- 3 clinical-stage programs
- Targets severe genetic disease markets
- Platform supports repeat launches
uniQure's Hemophilia B Gene Therapy Pipeline Gains Momentum
uniQure N.V.'s product development strategy centers on hemophilia B gene therapy, led by etranacogene dezaparvovec AMT-061, which posted 54% mean factor IX activity at 104 weeks in HOPE-B. AMT-060 deepens the same disease franchise, while AMT-130, AMT-191, and AMT-260 show repeat pipeline creation. As of 2025, uniQure had 3 clinical-stage programs.
| Asset | Stage | Key data |
|---|---|---|
| AMT-061 | Phase III | 54% mean FIX at 104 weeks |
| AMT-060 | Phase I/II | Same hemophilia B market |
| Pipeline | 3 clinical-stage | AMT-130, AMT-191, AMT-260 |
Diversification
Multiple CNS programs
uniQure N.V. is diversifying into 4 CNS programs outside hemophilia B: AMT-130, AMT-210, AMT-260, and AMT-161. This is a move into several central nervous system markets at once, spreading risk across different diseases and biology. In 2025, that portfolio mix gives uniQure more shots at value beyond a single hemophilia franchise.
Huntington’s, Parkinson’s and epilepsy
uniQure N.V. is diversifying into 3 distinct CNS markets: Huntington’s disease with AMT-130, Parkinson’s disease with AMT-210, and epilepsy with AMT-260. This is not one-disease expansion; each asset hits a different neurological target, which can spread clinical and commercial risk. That helps reduce dependence on the hemophilia B franchise and builds a broader long-term revenue base.
ALS and Alzheimer’s disease
uniQure N.V. is using AMT-161 and AMT-240 to enter two new neurodegenerative markets: ALS and autosomal dominant Alzheimer’s disease. ALS affects about 30,000 people in the United States at any time, while autosomal dominant Alzheimer’s disease is rare, at roughly 1% of Alzheimer’s cases. This is a true new-products, new-markets move in the Ansoff Matrix, aimed at severe unmet need.
Preclinical to Phase III spread
uniQure’s pipeline spans preclinical AMT-240 through Phase III HOPE-B, so the company is not tied to one development bet. That spread diversifies risk across early, mid, and late-stage assets, while also opening multiple future market shots if one program advances faster than others.
- Preclinical AMT-240 adds early optionality.
- Phase III HOPE-B adds late-stage value.
- Spread lowers single-asset dependence.
Rare-disease portfolio breadth
uniQure is diversified across 6 severe indications, not one market: hemophilia B, Huntington’s disease, Parkinson’s disease, epilepsy, ALS, and Alzheimer’s disease. That breadth shows a rare-disease platform built on gene therapy science, with multiple shots on goal across blood and CNS disorders. It is not a single-product story.
- 6 indications across 2 major disease areas
- Broad rare-disease platform, not one market
- Multiple pipeline shots on goal
uniQure’s 4 CNS Bets Diversify Risk Across 6 Indications
uniQure N.V. is using diversification in the Ansoff Matrix by pushing 4 CNS programs beyond hemophilia B: AMT-130, AMT-210, AMT-260, and AMT-161. That spreads clinical risk across 6 indications and gives the company more than one path to value in 2025/2026.
| Metric | Value |
|---|---|
| CNS programs | 4 |
| Indications | 6 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.